Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. - Wikidata - awgldk - TriplyDB

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

http://www.wikidata.org/entity/Q34617892

about

Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review Bisphosphonates: mechanism of action and role in clinical practice Male Osteoporosis in the Elderly Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound Food Fortification and Supplement Use-Are There Health Implications?Cancer treatment-related bone disease.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health and prostate cancer.Management of complications of prostate cancer treatment.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer Preventing bone complications in advanced prostate cancer Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass Update on the management of prostate cancer with goserelin acetate: patient perspectives Treatment and prevention of bone complications from prostate cancer.Denosumab in men receiving androgen-deprivation therapy for prostate cancer Androgen deprivation therapy for prostate cancer: new concepts and concerns.NCCN Task Force Report: Bone Health in Cancer Care.Update on medications with adverse skeletal effects Management of complications of androgen deprivation therapy in the older man.Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Contemporary therapeutic approaches targeting bone complications in prostate cancer Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy An update on the changing indications for androgen deprivation therapy for prostate cancer.Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.Management of bone metastases in refractory prostate cancer--role of denosumab.An update on androgen deprivation therapy for prostate cancer.Approach to the prostate cancer patient with bone disease Androgen deprivation therapy toxicity and management for men receiving radiation therapy Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.Towards a diagnostic and therapeutic consensus in male osteoporosis

P2860

Q24597422-8D8A507E-F17A-4D66-9F5E-A14C95606B43 Q24644708-FE0B1D9A-B6DB-434A-8429-09B6B08B77EC Q26784352-DED019BE-914C-40E4-B48F-D5EFB7D500A0 Q27021268-849DDFF0-8132-42E9-8664-789C80BD0EE4 Q28543939-7459A343-05A0-4E1B-8DB7-45CDBFB2338C Q30252188-6EDAB2DE-E63B-43BF-BBE3-38C7CC64A46D Q30438185-31662F2A-4E39-4889-BD22-202D19BD6808 Q33754036-4F3BBA70-A220-416D-9298-B462A12311CC Q33789201-EA63C44B-1FA3-45B0-8C8C-7C3508B505DA Q33977523-D74CC688-BAC4-47C7-B5C1-9B6A0048327E Q33977536-32B73A9A-7C88-4DB4-A308-61F3FEB278CC Q33978360-24980CDB-EDBB-4A96-B7F9-037A2FFD28E4 Q34023510-62FC3EEC-A4A2-4F18-A18D-D103D9DCD374 Q34111634-F1641DF9-58DA-413F-9E96-A34C1EB19E8D Q34339740-4BA34813-E7F1-4F1E-B9DF-C131D188D30C Q34389524-CAE74032-B82F-4DD6-8A41-D7C22A382CDB Q34418403-4F28DC51-646C-4D52-B651-CA1BE869029B Q34441944-7DCE8427-4EDB-4A20-BA20-DFFC1701FFE8 Q34570396-F75FE149-6547-4590-B0CF-CC390DE667A4 Q34617845-9E0D9131-A6A0-4E1C-8321-CC2476605C64 Q34617936-7ED10074-C5BE-4990-BE4E-D2C5C46A3A1B Q34748485-A140C4C4-8E98-436A-8F03-FC4BDE6D9A39 Q34782101-55154761-7A86-4DDB-9F72-A1CF9DB720FC Q34823216-392BC625-EFA1-425D-8F51-7946D6D408E7 Q34960686-EDBF837B-7334-4332-811F-8D8D316B1AA4 Q34960778-8E94FB9B-429C-4B88-B4DD-F8BFCCA806C4 Q35022212-C5E9F0E9-6967-45FD-8B67-D506C60CEA26 Q35206815-A12A8AF3-A797-4DE2-9023-16E8CC93B01D Q35549863-5841E98F-0784-453C-833D-AFCC132E220C Q35661057-57782D00-AAED-495D-8EE3-5EE7DFA03369 Q35689824-310CF2EB-44BB-4178-8EDD-CC35C7EF4926 Q35774987-57B88DEB-494D-4A7A-8D7B-C71852646F57 Q35779327-310A43A8-1846-440E-981A-E1B1E334A02A Q36059331-5AF1AB6F-4795-48F7-B798-367EBA489EB1 Q36283689-024AA96F-0EEF-492D-BC5B-72D966FB1363 Q36289952-A345D64E-C040-4A05-8B55-3EAC8F722043 Q36360754-E85314DC-0ED9-4EF9-8EF2-152F9F2568A6 Q36530136-1715EB52-B8C4-48FC-9902-160D4D3EF410 Q36553506-28C4B0AE-F25A-468F-A329-3AEFA9775126 Q36564415-6FA1D3ED-4568-4A20-9DC5-B1CA21860710

P2860

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

http://www.wikidata.org/entity/Q34617892

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Randomized controlled trial of ...... s in men with prostate cancer.

@ast

Randomized controlled trial of ...... s in men with prostate cancer.

@en

Randomized controlled trial of ...... s in men with prostate cancer.

@nl

type

label

Randomized controlled trial of ...... s in men with prostate cancer.

@ast

Randomized controlled trial of ...... s in men with prostate cancer.

@en

Randomized controlled trial of ...... s in men with prostate cancer.

@nl

prefLabel

Randomized controlled trial of ...... s in men with prostate cancer.

@ast

Randomized controlled trial of ...... s in men with prostate cancer.

@en

Randomized controlled trial of ...... s in men with prostate cancer.

@nl

P1433

Q34617892-4C4FA87F-3FA4-413C-B6C7-4762F37F7B1C

P1476

Q34617892-FF7BA65F-31F1-45E8-BAA7-77AF52F85151

P2093

Q34617892-6E6BE832-9053-4F16-BF80-B243B173BB91

Q34617892-976F4EFF-CD99-49DF-BCFD-4BAACD875D8A

Q34617892-D190F393-598B-4826-A2C3-25485EA95183

Q34617892-DBD9EE8C-A7EE-4904-BD09-3E242CB6D816

Q34617892-DE51F313-D80A-4117-8ABD-98798F730CE7

Q34617892-E5A73D08-7BD7-4C38-8DAD-A27BC2E2D338

P2860

Q34617892-0620A118-2F22-4723-A7FF-F6C5FA95F61A

Q34617892-1E5F7BFE-B138-4FDD-8CBD-5BDFD62EAB94

Q34617892-1E93CE73-BA37-4FB0-B5BD-ECBB3BD0E45E

Q34617892-233ED75E-91DF-4158-AA56-F1940C72E11F

Q34617892-2B89E0B0-D1C8-470F-AB36-E401BF7F47C6

Q34617892-3A81DC8B-ACCE-42F3-BAF8-E765F696D6B6

Q34617892-5E255A37-EB78-4797-84BC-7A842BC83FAB

Q34617892-5E913E3D-F671-42AC-9E80-9CEC8D8EDC93

Q34617892-67BE9B8D-3E94-48D6-86E1-72C46540E18B

Q34617892-8140CFDF-87B3-4DB4-A2E5-83588D3F9F62

P304

Q34617892-5A60A64C-16C6-448B-B6C0-18CB9378A9C6

P31

Q34617892-7A099919-FD9E-4DB6-B821-7F5659AFC841

P356

Q34617892-A1A9E23D-7361-4749-89B1-A77450E25BE8

P407

Q34617892-D4F14876-5007-44D5-8679-0298D782C2C9

P433

Q34617892-8FC12526-E5C0-426B-98D1-5786A5FE7786

P478

Q34617892-636A4D4B-A77D-4F6B-B9A3-62FA8317BAE5

P50

Q34617892-15F1EB26-5195-4F89-898F-67363229BFD7

Q34617892-BE26194C-84D6-4C07-93CF-6361EB2FA940

P577

Q34617892-FB93C98F-706F-44E3-8649-B550AA156F08

P698

Q34617892-FA1096C0-F738-49B1-99CE-E3D115894321

P932

Q34617892-63F6C32E-A213-4F1B-B75C-F54064B7FAD7

P356

JCO.2006.07.3361

P1433

Journal of Clinical Oncology

P1476

Randomized controlled trial of ...... ss in men with prostate cancer

@en

P2093

Donald S Kaufman

http://www.w3.org/2001/XMLSchema#string

Francis J McGovern

http://www.w3.org/2001/XMLSchema#string

Hang Lee

http://www.w3.org/2001/XMLSchema#string

Joel S Finkelstein

http://www.w3.org/2001/XMLSchema#string

Mary Anne Fallon

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

P304

1038-1042

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.3361

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

M. Dror Michaelson

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17369566

http://www.w3.org/2001/XMLSchema#string

P932

3047397

http://www.w3.org/2001/XMLSchema#string